- SID Score
- 7.8/10
- Fair value
- $290.53
- Generated
- Sep 2, 2026
- Model
- claude-haiku-4-5-20251001
Johnson & Johnson trades at $274.77 with a market capitalization of $505.8 billion and presents a mixed investment profile with moderate upside potential. The company demonstrates solid earnings consistency with a SID Score of 7.8/10, though valuation metrics suggest the stock is fairly valued to slightly overpriced relative to peers. Recent technical strength and analyst support provide some optimism, but conflicting price targets and modest dividend yield of 0.02% warrant careful consideration. The stock appears suitable for value-conscious investors seeking healthcare sector exposure with acceptable risk parameters.
JNJ's earnings performance demonstrates resilience with consistent beats against analyst estimates, including recent results showing $2.90 EPS versus $2.85 estimate in July 2026 and $2.70 versus $2.67 in April 2026. The P/E ratio of 20.30 sits above the healthcare sector average, suggesting the market has priced in growth expectations that may be challenging to exceed. Fair value estimates of $290.53 indicate 8.4% upside potential, though this represents modest appreciation potential for a company of JNJ's size and maturity. The company earns an A grade for Growth but only a C for Profitability, indicating that while top-line expansion is occurring, margin expansion may be constrained by operational pressures or increased competitive dynamics.
The stock trades above both its 50-day moving average of $259.69 and 200-day moving average of $240.88, establishing a constructive uptrend with the price positioned 5.8% above the intermediate-term average and 14.1% above the long-term average. An RSI(14) reading of 61.5 indicates the stock is approaching overbought conditions but has not yet entered the extreme zone above 70, suggesting room for modest continued appreciation without immediate pullback pressure. The technical setup supports the fair value estimate of $290.53, though momentum should be monitored as RSI levels above 70 have historically preceded consolidation periods. Current price positioning within the uptrend provides technical confirmation for positive sentiment, though the trajectory should remain the primary focus for tactical trading decisions.
Analyst & Insider Sentiment
The analyst consensus maintains a "Buy" rating; however, the average price target of $207.08 is significantly below the current price of $274.77, creating a notable disconnect that suggests substantial analyst pessimism or outdated projections that warrant investigation. Recent insider activity reflects mixed signals, with CEO Joaquin Duato executing a large net sell program (selling 654,249 shares while buying 399,258 shares on August 13, 2026), resulting in a net reduction of 254,991 shares despite the positive buy component. The insider selling pattern, while not definitively bearish, contradicts the bullish analyst consensus and may indicate executive caution regarding near-term valuation levels. This divergence between analyst recommendations and insider actions suggests uncertainty regarding the stock's trajectory and warrants closer monitoring of future insider trading activity.
The most significant risk is the substantial valuation gap between current price ($274.77) and analyst consensus target ($207.08), representing a potential 24.7% downside should analyst projections prove accurate or consensus narrows toward historical price levels. Profitability grade of C combined with modest dividend yield (0.02%) suggests limited margin of safety and reduced income generation relative to traditional dividend aristocrats in the healthcare sector. Insider selling activity by senior executives raises questions about management's confidence in current valuation, potentially signaling anticipated headwinds in pipeline execution or competitive pressures not yet reflected in earnings. Additional risks include pharmaceutical patent expirations, regulatory pressures on drug pricing, and execution challenges on major product launches that could constrain growth acceleration.
Johnson & Johnson represents a quality healthcare company trading at a fair to slightly elevated valuation, suitable primarily for investors with medium-term horizons seeking sector exposure rather than exceptional value opportunities. The 8.4% upside to fair value combined with modest dividend yield offers limited total return potential unless the company accelerates growth or improves profitability margins to justify the premium valuation. The strong analyst Buy rating is contradicted by both the depressed consensus price target and insider selling patterns, creating uncertainty that should be resolved through monitoring of upcoming earnings and strategic announcements. Conservative investors should await either a pullback to the $250-$260 range, improved earnings guidance, or resolution of the analyst-insider sentiment divergence before initiating significant new positions, though the company remains a fundamentally sound long-term healthcare holding.
